14:48 IST
NSE
Earnings Call
Accretion Pharmaceuticals Earnings Call: Key Takeaways
Accretion Pharmaceuticals reported strong FY26 performance with ₹89.63 cr total income and 10.8% PAT margin, driven by export growth.
ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
1 announcement with these filters
Accretion Pharmaceuticals reported strong FY26 performance with ₹89.63 cr total income and 10.8% PAT margin, driven by export growth.